If participant is enrolled in Phase 1, the dose of venetoclax participant receives will depend on when participant joins this study. The first group of participants will receive the highest dose level of venetoclax. If there are no intolerable side effects at this dose, Phase 1 will close and Phase 2 will begin. If intolerable side effects are seen, a new group of participants will be enrolled to receive a lower dose of venetoclax than the group before it. This will continue until the highest tolerable dose of venetoclax is found. This is called dose escalation.